Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ionis Invests For The Future In New Technologies, Manufacturing Innovation

Antisense Pioneer Looks Beyond Brain, Heart And RNA

May 30 2023

• By Mandy Jackson

3D Model of DNA/RNA — Ionis is investing beyond RNA in gene-editing medicines • Source: Shutterstock

Related Content

Ionis Enters $500m+ Agreement With Royalty Pharma To Help Fund Late-Stage Pipeline

Jan 11 2023

Ionis Finds Its Footing Ahead Of Its First Big Commercial Step

May 26 2023

Ionis Enlists Bicycle To Open Up New Antisense Targets In Bounce-Back Bid

Jul 15 2021

Ionis Partners With Metagenomi To Expand Its Genetic Medicines Capabilities

Nov 14 2022

Related Companies

Ionis Pharmaceuticals, Inc.

Bicycle Therapeutics, plc

Metagenomi, Inc.

AstraZeneca PLC

Royalty Pharma plc

Biogen, Inc.

Additional Topics

Innovation Platform Technologies Manufacturing Strategy Growth Companies Commercial BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window